20 years of Cure Parkinson's
We’re here for the cure! This year marks 20 years since Cure Parkinson’s was founded by four people living with Parkinson’s who felt that nobody was taking a cure seriously enough and that there was an urgent need for a focused approach to curative research...
Learn more
Mo better for TEVA with Modag?
This week the pharmaceutical company TEVA Pharmaceuticals Industries Ltd has announced a deal with a small German biotech firm called MODAG. The two companies are forming a strategic collaboration on the exclusive worldwide licensing and development of MODAG’s lead compound anle138b. Anle138b is a small molecule inhibitor of the believed […]
Webinar: Deep Brain Stimulation (DBS)
Presented by the Journal of Parkinson’s Disease, Cure Parkinson’s and Van Andel Institute. In this webinar, Professor Patrik Brundin chairs a panel of experts featuring: Professor Helen Bronte-Stewart Stanford University, California; Professor Tom Foltynie, University College London and David Jones, a pharma entrepreneur who has…
The Tom Isaacs Charity Golf Day 2021
On Thursday 14 October, 54 players enjoyed a round of golf in memory of Cure Parkinson’s late Co-founder and President, Tom Isaacs, raising over £2,000 for Parkinson’s research. The annual Tom Isaacs Memorial Golf Day, kindly hosted each year by Denham Golf Club, is one…
Prime Minister awards ‘Points of Light’ to our Fundraiser of the Year
Meriel Buxton, our 2020 Fundraiser of the Year, has received Prime Minister Boris Johnson’s Points of Light award.
New potential drugs for repurposing in Parkinson’s
The development of new drugs is a long and expensive process, taking many years of funding to bring new therapeutics to treat diseases. Drug repurposing offers a means of rapidly testing already available medicines in diseases that they were not originally approved for.